# Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy

> **NCT01565096** · PHASE4 · UNKNOWN · sponsor: **ikfe-CRO GmbH** · enrollment: 44 (estimated)

## Conditions studied

- Diabetes Mellitus Type II

## Interventions

- **DRUG:** Metformin
- **DRUG:** Metformin
- **DRUG:** Vildagliptin
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT01565096
- **Lead sponsor:** ikfe-CRO GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-11
- **Primary completion:** 2012-11
- **Final completion:** —
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2012-03-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01565096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01565096, "Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT01565096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*